Tendcart

TENDCART's bioactive matrix technology holds particular promise in osteoporosis management, where the compromised bone-cartilage interface presents unique therapeutic challenges. Its scaffold components are designed to support structural repair at the subchondral level — addressing the root cause of joint degeneration in osteoporotic bone. By promoting integrated bone and cartilage repair, TENDCART aims to offer osteoporosis patients a treatment option that addresses joint degeneration at its structural source, complementing systemic antiresorptive therapies.

Preclinical models of osteoporosis-related OA show TENDCART promoting mineralisation of the tidemark zone and restoration of the osteochondral unit — a unique mechanism of action with significant implications for osteoporosis-driven joint disease.

Bioactive scaffold components support osteochondral repair by providing structural guidance for both chondrocyte and osteoblast lineage cells at the bone-cartilage interface. Growth factor analogues stimulate osteocalcin and collagen type II expression in preclinical models of osteoporosis-related subchondral bone loss. Potential to arrest the vicious cycle of subchondral bone deterioration and cartilage loss that characterises osteoporosis-related joint degeneration. Complementary mechanism to antiresorptive drugs; designed to work synergistically within existing osteoporosis treatment frameworks rather than replace them.

Osteoporosis-associated OA is a designated sub-population within the TENDCART Phase III programme, with dedicated efficacy endpoints including DXA and MRI outcomes. Collaboration with leading bone metabolism research centres is underway to characterise osteochondral repair mechanisms in greater clinical detail. Regulatory fast-track designation is being pursued in key markets given the significant unmet need in osteoporosis-related joint disease management. Clinicians managing osteoporosis patients are encouraged to register interest in TENDCART clinical trial participation through the medical affairs contact portal.

Unlike conventional analgesics that manage pain symptoms, TENDCART targets the structural tissue damage that drives persistent pain in cartilage and tendon disorders. By promoting genuine tissue repair, TENDCART aims to offer durable pain relief that reduces and potentially eliminates the need for ongoing symptomatic treatments. This disease-modifying approach to pain management represents a paradigm shift — addressing the underlying pathology rather than masking its symptoms, with early data suggesting sustained pain reduction well beyond treatment completion.

For patients trapped in cycles of escalating analgesic use, TENDCART's regenerative mechanism offers a credible exit pathway — restoring tissue integrity and eliminating the structural pain source rather than suppressing the pain signal alone.

Tissue regeneration reduces the structural pain generators (cartilage erosion, tendon micro-tears) that drive persistent nociceptor activation in chronic musculoskeletal pain. Early data suggests pain reduction scores continue to improve after the acute treatment phase, consistent with the progressive nature of tissue repair rather than symptom suppression. Potential to break the chronification cycle of structural damage → inflammation → sensitisation → further damage that characterises progressive joint and tendon pain disorders. Anti-inflammatory bioactive components concurrently suppress the inflammatory mediators responsible for peripheral sensitisation and central pain amplification.

Chronic knee pain from cartilage defects, refractory Achilles tendinopathy, and persistent patellar tendon pain are the primary pain indications in the TENDCART Phase III programme. Pain outcomes assessed using NRS, KOOS, VISA-A, and PROMIS Pain Interference scales to comprehensively characterise the analgesic benefit profile across indications. Combination with structured pain rehabilitation programmes is planned in trial arms to evaluate the additive benefit of TENDCART within multimodal pain pathways. Pain management specialists and rheumatologists interested in the TENDCART early access programme should contact the medical affairs team for eligibility information.